Skip to main content

This job has expired

You will need to login before you can apply for a job.

Director / Associate Director, Discovery Program Lead

Employer
Omega Therapeutics
Location
Cambridge, MA, United States
Start date
Jan 8, 2021

View more

Discipline
Science/R&D, Cell Biology, Genetics, Oncology
Required Education
Doctorate/PHD/MD
Position Type
Full time
Hotbed
Genetown, NextGen Bio

Job Details

About Omega Therapeutics:

Omega Therapeutics is a privately-held, development-stage biotechnology company pioneering the field of epigenomic programming to precisely regulate and control the human genome to treat and cure disease. Omega's breakthrough science has enabled it to tap into nature's universal operating system, that epigenetically controls the human genome, to target the most fundamental genomic processes which fuel cellular growth, differentiation, and gene expression. Omega Therapeutics was founded by Flagship Pioneering in 2017 and currently has eight programs in various stages of preclinical development. The Company is strategically pursuing specific disease targets that have not been successfully addressed through conventional modalities, including liver disease, serious inflammatory conditions, acute respiratory distress syndrome (ARDS) and certain oncology indications, among others. Omega's mission is to transform medicine and deliver the therapies of tomorrow.

About the Role:

Omega Therapeutics, Inc. is seeking a Director / Associate Director, Discovery Program Lead (commensurate with experience) to join our discovery team to develop and advance our transcription modulation programs, from early development to proof-of-concept and beyond. The successful candidate must be scientifically motivated self-starter, capable of working with minimal supervision, conducting and critically analyzing experiments. The successful candidate will collaborate with other senior project scientists and research associates to design and complete in vitro proof-of-concept and in vivo translational studies on aggressive timelines.

We are looking for enthusiastic, detail oriented and highly motivated individuals with a passion for bringing novel medicines to patients and who are comfortable working on a fast-paced scientific team.

Key Responsibilities:
  • Utilize technical knowledge of cell and molecular biology and genomics tools to support platform build and therapeutic program development with a focus on cancer
  • Must be comfortable following developed protocols, but a demonstrable ability to develop new techniques and assays
  • Provide support for cell-based assays and optimization of new sequencing-based protocols

Required Skills:
  • Well versed in techniques that include but are not limited to mammalian cell culture, transfections, RNA/DNA/protein isolation and analysis, qPCR, gel electrophoresis, ChIP, and bisulfite conversion
  • Extensive experience with cancer tumor models (xenograft, PDX, syngeneic)
  • Demonstrated ability in progression of discovery programs into development
  • Detail oriented with experience running and developing medium to high-throughput assays
  • Strong presentation and excellent communication skills, both oral and written
  • Demonstrated ability in working with highly skilled project teams in a fast paced, entrepreneurial and technical setting
  • Highly adaptable and responsive to technical and business opportunities - comfortable delivering against challenging project needs and timelines

Required Qualifications:
  • Ph.D. (Scientist) in Cell or Molecular Biology, Genetics, Cancer Biology or a related field
  • 5+ years industry experience
  • Experience with genetic / genomic research and techniques preferred

Company

Omega Therapeutics is a publicly held, development-stage biotechnology company pioneering a new class of DNA-sequence-targeting, mRNA-encoded therapeutics to transform human medicine. The OMEGA Epigenomic Programming™ platform harnesses the power of epigenetics, the mechanism that systematically controls every aspect of an organism’s life from cell genesis, to growth and differentiation. The OMEGA platform has identified thousands of novel DNA-sequence-based epigenomic targets within Insulated Genomic Domains (IGDs), referred to as EpiZips™. IGDs represent the three-dimensional, distinct, and evolutionarily conserved architecture of the genome, and are the fundamental structural and functional units of gene control and cell differentiation. They act as the “control room” of biology. The OMEGA platform examines alterations in IGDs leading to aberrant gene expression, a cause of most disease. It then leverages its database of EpiZips to identify appropriate intervention points within the IGDs and rationally designs biologically engineered, modular, and programmable mRNA-encoded epigenetic medicines, called Omega Epigenomic Controllers™, to target EpiZips for Precision Genomic Control™. With its computation- and data-first approach, Omega Therapeutics is currently advancing a broad pipeline of programs that span regenerative medicine, multigenic diseases including immunology, oncology, and select monogenic diseases.

Twitter

Company info
Website
Phone
(617) 949-4359
Location
140 First Street
Cambridge
MA
02141
United States

Get job alerts

Create a job alert and receive personalized job recommendations straight to your inbox.

Create alert